Remetinostat, also named SHP-141, inhibits HDAC1, HDAC3, and HDAC6 and was designed to exert efficacy specifically and locally in the skin.658 Clinical trials have examined remetinostat in early stage CTCL. Here, HDAC1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.